Beta-nicotinamide mononucleotide is an NAD+ precursor. Oral NMN raises circulating NAD-related metabolites in short human trials, but a higher blood NAD+ measurement is a biochemical surrogate and does not establish improved organ function or slower aging.
What it is, why people use it, the evidence, and what to know before trying it.
Regulatory status: dietary supplement (vitamin B3-related NAD+ precursor). Not a prescription drug in any major market as of August 2026. A pharmaceutical-grade microcrystalline polymorph (MIB-626, Metro International Biotech) is in company-sponsored drug trials
Mechanism evidence: human
NMN reliably raises blood NAD+ (or NAD++NADH) at 250–2,000 mg/day. That is a surrogate. The only gold-standard metabolic win is Yoshino 2021: +25% muscle insulin-stimulated glucose disposal in 13 overweight prediabetic postmenopausal women, with no change in fasting glucose, HbA1c, liver or fat insulin sensitivity, lipids, BP, or muscle NAD+. HOMA-IR trials and the 2025 Zhang meta-analysis of 12 RCTs (n=513) do not show a glycaemic or lipid benefit. Liao improved ventilatory threshold, not VO2max, in already-training runners. Muscle-mass trials are null; function signals (gait, 6-minute walk, afternoon 5-STS) are small, short, and often industry-funded. Pencina’s −19 mg/dL LDL and −7 mmHg diastolic BP appeared only at 2 g/day of a pharmaceutical polymorph for 28 days. Sleep evidence is mixed. **Human longevity evidence is absent.** **Confidence: weak** for any clinical outcome a person would notice or that would change a hard endpoint; **moderate** for blood-NAD raising and short-term tolerability at 250–1,250 mg/day.
Confidence: moderate
Known side effects, interactions and use limits from reviewed sources.
Short trials generally report tolerability over weeks to a few months, but long-term safety is not established. Product identity and purity are important because consumer NMN is not equivalent to pharmaceutical trial material. Pregnancy, cancer treatment, liver or kidney disease and medication use warrant clinician review.
Public protocols that include NMN (β-nicotinamide mononucleotide). Open one to see the full context and source.
Amount and timing patterns reported in public protocols; these are observations, not instructions. Private and hidden usage is excluded.
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
Continue into interventions that appear alongside this one.